Research Study

A 12-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients With Moderate to Severe Plaque Psoriasis With a Long-Term Extension Period
Principal Investigator 
Youwen Zhou

Overview

Body Locations and Systems 
Psoriasis
ClinicalTrials.gov# 
NCT01646177
Status 
Closed to Recruitment
Study Start/End 
Aug 27, 2012 to Dec 29, 2017
Locations 
Vancouver General Hospital
Name/Title 
Satvir Dhoot, Research Coordinator
Phone 
604-875-5296
Purpose of Study 

This study will assess the safety and efficacy of ixekizumab (LY2439821), compared to etanercept and placebo in participants with moderate to severe chronic plaque psoriasis.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.